{"entity":{"id":"inv-8989","kind":"drug","name":"INV-8989","aka":[],"tldr":"INV-8989 is an experimental form not stated by the company or the registry from Shenzhen Ionova Life Sciences, in phase 1 trials for colorectal cancer, non-small cell lung cancer and pancreatic adenocarcinoma and other cancers.","summary":"INV-8989 is a form not stated by the company or the registry from Shenzhen Ionova Life Sciences. Tested in solid tumours harbouring KRAS G12D mutations; neither the registry nor the company website states the molecule's mechanism or modality. Its furthest stage is phase 1, for colorectal cancer, non-small cell lung cancer, pancreatic adenocarcinoma and ovarian cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 first-in-human, recruiting, started 2026-06-01 (registry). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Shenzhen Ionova Life Sciences: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07610798"},{"label":"Shenzhen Ionova Life Sciences: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07610798"},{"label":"ClinicalTrials.gov: trials of INV-8989","url":"https://clinicaltrials.gov/search?intr=INV-8989"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal","nsclc","pancreatic","ovarian","endometrial","biliary-tract-cancer"],"sections":[],"technologies":[],"targets":["kras"],"drugs":[],"companies":["shenzhen-ionova-life-sciences"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07610798"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"INV-8989","modality":"Form not stated by the company or the registry","mechanism":"Tested in solid tumours harbouring KRAS G12D mutations; neither the registry nor the company website states the molecule's mechanism or modality.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/inv-8989/","neighbours":{"cancer":[{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"company":[{"id":"shenzhen-ionova-life-sciences","kind":"company","name":"Shenzhen Ionova Life Sciences","route":"/companies/shenzhen-ionova-life-sciences/"}],"trial":[{"id":"nct07610798","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations","route":"/trials/nct07610798/"}]}}